Table 1.
Characteristic | miR-639 (%) | P | Foxc1 (%) | P | ||
---|---|---|---|---|---|---|
No. low/− expression | No. high expression | No. low/− expression | No. high expression | |||
Sex | ||||||
Male | 30 (54.5) | 25 (45.5) | 0.579 | 27 (42.5) | 28 (57.5) | 0.767 |
Female | 18 (48.6) | 19 (51.4) | 17 (54.3) | 20 (45.7) | ||
Age (years) | ||||||
<50 | 21 (53.8) | 18 (46.2) | 0.783 | 15 (38.2) | 24 (61.8) | 0.123 |
≥50 | 27 (50.9) | 26 (49.1) | 29 (56.1) | 24 (43.9) | ||
Metastasis | ||||||
N0 | 19 (39.6) | 29 (60.4) | 0.012 | 28 (59.5) | 20 (40.5) | 0.035 |
N1–N2 | 29 (65.9) | 15 (34.1) | 16 (33.3) | 28 (66.7) | ||
Clinical stage | ||||||
I–II | 14 (35.0) | 26 (65.0) | 0.004 | 24 (43.2) | 16 (56.8) | 0.040 |
III–IV | 34 (65.4) | 18 (34.6) | 20 (54.8) | 32 (45.2) | ||
Status | ||||||
Survival | 21 (41.2) | 30 (58.8) | 0.019 | 31 (64.3) | 20 (35.7) | 0.006 |
Death | 27 (65.9) | 14 (34.1) | 13 (27.3) | 28 (72.7) |